Rhodes Jason P

DirectorDyne Therapeutics, Inc. (DYN) · full profile →Form 4 · filed Apr 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.1M
Net Open-Market Flow
-$7.1M
Transactions
12
12 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 27, 2026Sell(S)36K$18.15$652K1.2M
Apr 27, 2026Sell(S)894$18.15$16K10K
Apr 27, 2026Sell(S)46K$18.15$830K1.6M
Apr 27, 2026Sell(S)91K$18.15$1.7M5.1M
Apr 24, 2026Sell(S)710$18.48$13K11K
Apr 24, 2026Sell(S)36K$18.48$672K1.7M
Apr 24, 2026Sell(S)72K$18.48$1.3M5.1M
Apr 24, 2026Sell(S)29K$18.48$528K1.2M
Apr 23, 2026Sell(S)19K$19.19$370K1.7M
Apr 23, 2026Sell(S)15K$19.19$291K1.3M
Apr 23, 2026Sell(S)377$19.19$7K11K
Apr 23, 2026Sell(S)38K$19.19$735K5.2M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001577014-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly: